NCT02408185View on ClinicalTrials.gov

Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Critical Illness
Interventions
DRUG

Colistin 6 million units + 240mg/8h

240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)

DRUG

Colistin 6 million units + 360mg/12h

360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)

Trial Locations (1)

41013

Hospital Universitario Virgen del Rocío, Seville

All Listed Sponsors
lead

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER

NCT02408185 - Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients | Biotech Hunter | Biotech Hunter